Karyopharm Therapeutics
Inc. KPTI, a clinical-stage pharmaceutical company, announced today
that it has expanded its operational footprint with a wholly-owned European
subsidiary and appointed Ran Frenkel, an international executive with
significant experience managing European clinical operations and regulatory
affairs activities within the biopharmaceutical industry, as Executive Vice
President, Worldwide Clinical Development. Reporting to Sharon Shacham, PhD,
MBA, President and Chief Scientific Officer of Karyopharm, Mr. Frenkel will
be responsible for managing the new subsidiary, Karyopharm Europe GmbH,
which will be headquartered in Munich, Germany and will provide the
corporate structure necessary to support Karyopharm's expanded clinical and
regulatory activities in Europe.
"The establishment of this European subsidiary will provide a strong base of
clinical, medical and regulatory expertise to support our
registration-directed clinical studies, which are being conducted primarily
in Europe and the United States, as well as in Canada and other countries,"
said Sharon Shacham, PhD, MBA, President and Chief Scientific Officer of
Karyopharm. "With a growing team in Europe and Ran at the helm, we have the
resources and support to manage our current and planned clinical trials and
to build additional European infrastructure as needed."
Ran Frenkel has more than 20 years of experience in the international
biopharmaceutical industry encompassing clinical, regulatory, business
development and commercial operations activities. Prior to joining
Karyopharm Europe GmbH, Mr. Frenkel held a number of senior management roles
in Europe, Israel and the United States, most recently as Managing Director
EMEA for Clinipace Worldwide, an international clinical research
organization, where he had responsibility for the overall management of the
organization in Europe, the Middle East and Africa. Prior to joining
Clinipace Worldwide, Mr. Frenkel established and managed the Israeli office
of PFC Pharma Focus AG, which was acquired by Clinipace in 2011, and he held
the position of Managing Director at Actelion Pharmaceuticals with
responsibility for all science and business affairs of the company in
Israel.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in